EQS-News: Eckert & Ziegler on Track as Planned and Achieves Another Record Year in 2025

Fiscal Year 2025 (preliminary):

• Sales: approx. € 312 million (PY: € 295.8 million)
• EBIT before special items: approx. € 78 million (PY: € 65.9 million)
• Net income: approx. € 48 million (PY: € 33.3 million)

Berlin, 29 January 2026. According to preliminary, unaudited figures for the 2025 financial year, Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of around € 312 million and adjusted EBIT of around € 78 million. Sales are up around 5% on the previous year, while adjusted EBIT is up by around 18%. Net profit (from continuing and discontinued operations), which is only reported here for comparison purposes, rose to around € 48 million (previous year: € 33.3 million).

The forecast for the 2026 financial year will be published on 26 March 2026 together with the complete, audited annual financial statements for the 2025 financial year.

About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDax index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com